F ate Therapeutics (NASDAQ:FATE) stock closed 12% higher Monday after soaring as much as 73% on news that the first patient in the company's Phase 1 Autoimmunity study for its CAR T-cell therapy ...

Looking ahead, Fate Therapeutics has several potential catalysts that could significantly impact its market position. The stock currently trades below its InvestingPro Fair Value, suggesting ...